The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Injectable Anthelmintic Drugs-Global Market Insights and Sales Trends 2024
Synopsis
The global Injectable Anthelmintic Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Injectable Anthelmintic Drugs in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Veterinary Pharmacies, are propelling Injectable Anthelmintic Drugs market. Benzimidazoles, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Piperazine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Injectable Anthelmintic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Injectable Anthelmintic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Injectable Anthelmintic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Injectable Anthelmintic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Injectable Anthelmintic Drugs covered in this report include Novartis, Cipla, Sun Pharmaceutical Industries, Amneal Pharmaceuticals, Zoetis, GlaxoSmithKline, Bayer, Merck and Boehringer Ingelheim International, etc.
The global Injectable Anthelmintic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Cipla
Sun Pharmaceutical Industries
Amneal Pharmaceuticals
Zoetis
GlaxoSmithKline
Bayer
Merck
Boehringer Ingelheim International
Global Injectable Anthelmintic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Injectable Anthelmintic Drugs market, Segment by Type:
Benzimidazoles
Piperazine
Imidazothiazole
Spiroindoles
Others
Global Injectable Anthelmintic Drugs market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Veterinary Pharmacies
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Injectable Anthelmintic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Injectable Anthelmintic Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Injectable Anthelmintic Drugs in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Veterinary Pharmacies, are propelling Injectable Anthelmintic Drugs market. Benzimidazoles, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Piperazine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Injectable Anthelmintic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Injectable Anthelmintic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Injectable Anthelmintic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Injectable Anthelmintic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Injectable Anthelmintic Drugs covered in this report include Novartis, Cipla, Sun Pharmaceutical Industries, Amneal Pharmaceuticals, Zoetis, GlaxoSmithKline, Bayer, Merck and Boehringer Ingelheim International, etc.
The global Injectable Anthelmintic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Cipla
Sun Pharmaceutical Industries
Amneal Pharmaceuticals
Zoetis
GlaxoSmithKline
Bayer
Merck
Boehringer Ingelheim International
Global Injectable Anthelmintic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Injectable Anthelmintic Drugs market, Segment by Type:
Benzimidazoles
Piperazine
Imidazothiazole
Spiroindoles
Others
Global Injectable Anthelmintic Drugs market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Veterinary Pharmacies
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Injectable Anthelmintic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Injectable Anthelmintic Drugs
1.1 Injectable Anthelmintic Drugs Market Overview
1.1.1 Injectable Anthelmintic Drugs Product Scope
1.1.2 Injectable Anthelmintic Drugs Market Status and Outlook
1.2 Global Injectable Anthelmintic Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Injectable Anthelmintic Drugs Market Size by Region (2018-2029)
1.4 Global Injectable Anthelmintic Drugs Historic Market Size by Region (2018-2023)
1.5 Global Injectable Anthelmintic Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Injectable Anthelmintic Drugs Market Size (2018-2029)
1.6.1 North America Injectable Anthelmintic Drugs Market Size (2018-2029)
1.6.2 Europe Injectable Anthelmintic Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Injectable Anthelmintic Drugs Market Size (2018-2029)
1.6.4 Latin America Injectable Anthelmintic Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Injectable Anthelmintic Drugs Market Size (2018-2029)
2 Injectable Anthelmintic Drugs Market by Type
2.1 Introduction
2.1.1 Benzimidazoles
2.1.2 Piperazine
2.1.3 Imidazothiazole
2.1.4 Spiroindoles
2.1.5 Others
2.2 Global Injectable Anthelmintic Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Injectable Anthelmintic Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Injectable Anthelmintic Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Injectable Anthelmintic Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Injectable Anthelmintic Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Injectable Anthelmintic Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Injectable Anthelmintic Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Injectable Anthelmintic Drugs Revenue Breakdown by Type (2018-2029)
3 Injectable Anthelmintic Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.1.4 Veterinary Pharmacies
3.1.5 Others
3.2 Global Injectable Anthelmintic Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Injectable Anthelmintic Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Injectable Anthelmintic Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Injectable Anthelmintic Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Injectable Anthelmintic Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Injectable Anthelmintic Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Injectable Anthelmintic Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Injectable Anthelmintic Drugs Revenue Breakdown by Application (2018-2029)
4 Injectable Anthelmintic Drugs Competition Analysis by Players
4.1 Global Injectable Anthelmintic Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Injectable Anthelmintic Drugs as of 2022)
4.3 Date of Key Players Enter into Injectable Anthelmintic Drugs Market
4.4 Global Top Players Injectable Anthelmintic Drugs Headquarters and Area Served
4.5 Key Players Injectable Anthelmintic Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Injectable Anthelmintic Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Injectable Anthelmintic Drugs Products, Services and Solutions
5.1.4 Novartis Injectable Anthelmintic Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis Recent Developments
5.2 Cipla
5.2.1 Cipla Profile
5.2.2 Cipla Main Business
5.2.3 Cipla Injectable Anthelmintic Drugs Products, Services and Solutions
5.2.4 Cipla Injectable Anthelmintic Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Cipla Recent Developments
5.3 Sun Pharmaceutical Industries
5.3.1 Sun Pharmaceutical Industries Profile
5.3.2 Sun Pharmaceutical Industries Main Business
5.3.3 Sun Pharmaceutical Industries Injectable Anthelmintic Drugs Products, Services and Solutions
5.3.4 Sun Pharmaceutical Industries Injectable Anthelmintic Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Amneal Pharmaceuticals Recent Developments
5.4 Amneal Pharmaceuticals
5.4.1 Amneal Pharmaceuticals Profile
5.4.2 Amneal Pharmaceuticals Main Business
5.4.3 Amneal Pharmaceuticals Injectable Anthelmintic Drugs Products, Services and Solutions
5.4.4 Amneal Pharmaceuticals Injectable Anthelmintic Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Amneal Pharmaceuticals Recent Developments
5.5 Zoetis
5.5.1 Zoetis Profile
5.5.2 Zoetis Main Business
5.5.3 Zoetis Injectable Anthelmintic Drugs Products, Services and Solutions
5.5.4 Zoetis Injectable Anthelmintic Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Zoetis Recent Developments
5.6 GlaxoSmithKline
5.6.1 GlaxoSmithKline Profile
5.6.2 GlaxoSmithKline Main Business
5.6.3 GlaxoSmithKline Injectable Anthelmintic Drugs Products, Services and Solutions
5.6.4 GlaxoSmithKline Injectable Anthelmintic Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 GlaxoSmithKline Recent Developments
5.7 Bayer
5.7.1 Bayer Profile
5.7.2 Bayer Main Business
5.7.3 Bayer Injectable Anthelmintic Drugs Products, Services and Solutions
5.7.4 Bayer Injectable Anthelmintic Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Bayer Recent Developments
5.8 Merck
5.8.1 Merck Profile
5.8.2 Merck Main Business
5.8.3 Merck Injectable Anthelmintic Drugs Products, Services and Solutions
5.8.4 Merck Injectable Anthelmintic Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Merck Recent Developments
5.9 Boehringer Ingelheim International
5.9.1 Boehringer Ingelheim International Profile
5.9.2 Boehringer Ingelheim International Main Business
5.9.3 Boehringer Ingelheim International Injectable Anthelmintic Drugs Products, Services and Solutions
5.9.4 Boehringer Ingelheim International Injectable Anthelmintic Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Boehringer Ingelheim International Recent Developments
6 North America
6.1 North America Injectable Anthelmintic Drugs Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Injectable Anthelmintic Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Injectable Anthelmintic Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Injectable Anthelmintic Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Injectable Anthelmintic Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Injectable Anthelmintic Drugs Market Dynamics
11.1 Injectable Anthelmintic Drugs Industry Trends
11.2 Injectable Anthelmintic Drugs Market Drivers
11.3 Injectable Anthelmintic Drugs Market Challenges
11.4 Injectable Anthelmintic Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
